The Pathogenesis, Treatment and Prevention of Osteoporosis in Men
- 13 December 2012
- journal article
- review article
- Published by Springer Nature in Drugs
- Vol. 73 (1) , 15-29
Abstract
Testosterone stimulates longitudinal and appositional growth during childhood, whereas estrogen induces epiphysial closure. During adulthood, testosterone continues to stimulate periosteal growth, whereas estrogen is important for the maintenance of trabecular bone mass and structure. In males, testosterone is aromatized to estradiol. Both free and bioavailable plasma levels of testosterone and estradiol decrease with age in males, and fracture risk is associated with low estradiol levels. Testosterone may increase muscle mass and prevent fractures related to falls. Younger hypogonadal males should be treated with testosterone to attain peak bone mass and increase bone mineral density (BMD). Older hypogonadal males should be treated in cases of osteoporosis, reduced muscle strength and increased risk of falling. Secondary hyperparathyroidism caused by calcium and vitamin D insufficiency may reduce bone mass and strength and increase fracture risk and should be avoided. Since calcium supplementation has been associated with an increased risk of cardiovascular complications and renal stones, the dose should be tailored to the habitual daily calcium intake. Lifestyle-related risk factors (smoking, alcohol consumption, lack of physical activity and low body weight) should be addressed. The antifracture efficacy of antiresorptive and anabolic treatment for osteoporosis has not been documented in larger randomized controlled studies. However, changes in BMD and bone markers suggest similar effects in males and females of bisphosphonates (alendronate, risedronate, ibandronate, zoledronic acid), nasal calcitonin, denosumab and teriparatide (parathyroid hormone [1–34]). The antiresorptive drugs should be used in males with BMD T-score less than −2.5 and one or more risk factors, or with hip and vertebral fractures. It seems appropriate to recommend a higher cut-off T-score (e.g. less than −1.0 standard deviation [SD]) in glucocorticoid-induced osteoporosis and in patients receiving androgen deprivation therapy because of the fast initial bone loss. Anabolic treatment should be used in more severe spinal fracture cases, including glucocorticoid-induced osteoporosis.Keywords
This publication has 122 references indexed in Scilit:
- Toremifene Decreases Vertebral Fractures in Men Younger Than 80 Years Receiving Androgen Deprivation Therapy for Prostate CancerJournal of Urology, 2011
- Towards a diagnostic and therapeutic consensus in male osteoporosisOsteoporosis International, 2011
- Estimates of the proportion of older white men who would be recommended for pharmacologic treatment by the new US national osteoporosis foundation guidelinesJournal of Bone and Mineral Research, 2010
- Update in Male OsteoporosisThe Journal of Clinical Endocrinology & Metabolism, 2010
- Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate CancerNew England Journal of Medicine, 2009
- Androgens and boneSteroids, 2009
- Primary hyperparathyroidism and the skeletonClinical Endocrinology, 2008
- Correlations between Serum Testosterone, Estradiol, and Sex Hormone-Binding Globulin and Bone Mineral Density in a Diverse Sample of MenThe Journal of Clinical Endocrinology & Metabolism, 2008
- Osteoporosis in MenEndocrine Reviews, 2008
- Vitamin D DeficiencyNew England Journal of Medicine, 2007